Dendritic Cell-Based Immunotherapy Targeting Synthesized Peptides for Advanced Biliary Tract Cancer

Journal of Gastrointestinal Surgery

Volumn 17, Issue 9, 2013, Pages 1609-1617

  Kobayashi, Masanori ^a,e   Sakabe, Tomoyo ^a   Abe, Hirofumi ^b   Tanii, Mitsugu ^c   Takahashi, Hidenori ^c   Chiba, Asako ^d   Yanagida, Eri ^d   Shibamoto, Yuta ^e   Ogasawara, Masahiro ^f   Tsujitani, Shun ichi ^g   Koido, Shigeo ^h   Nagai, Kazuhiro ⁱ   Shimodaira, Shigetaka ^j   Okamoto, Masato ^k   Yonemitsu, Yoshikazu ^l   Suzuki, Noboru ^m   Nagaya, Masaki ^d,m  

^a Seren Clinic Nagoya   (Japan)

^b Seren Clinic Kobe   (Japan)

^c Seren Clinic Fukuoka   (Japan)

^d Seren Clinic   (Japan)

^e NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^f SAPPORO HOKUYU HOSPITAL   (Japan)

^g NATIONAL CENTER FOR GLOBAL HEALTH AND MEDICINE   (Japan)

^h JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

ⁱ NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^j SHINSHU UNIVERSITY HOSPITAL   (Japan)

^k KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^l KYUSHU UNIVERSITY   (Japan)

^m ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

more..

Author keywords

Dendritic cell; Immunotherapy and biliary tract cancer; MUC1; WT1

Indexed keywords

CANCER VACCINE; MUC1 PROTEIN, HUMAN; MUCIN 1; WT1 PROTEIN; WT1 PROTEIN, HUMAN;

ACTIVE IMMUNIZATION; AGED; ARTICLE; BILE DUCT CARCINOMA; BILE DUCT TUMOR; BILIARY TRACT TUMOR; DENDRITIC CELL; EVALUATION STUDY; FEMALE; GALLBLADDER TUMOR; HEPATIC DUCT; HUMAN; IMMUNOLOGY; INTRAHEPATIC BILE DUCT; MALE; METHODOLOGY; MIDDLE AGED; MORTALITY; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, EXTRAHEPATIC; BILE DUCTS, INTRAHEPATIC; BILIARY TRACT NEOPLASMS; CANCER VACCINES; CHOLANGIOCARCINOMA; DENDRITIC CELLS; FEMALE; GALLBLADDER NEOPLASMS; HUMANS; IMMUNOTHERAPY, ACTIVE; MALE; MIDDLE AGED; MUCIN-1; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; WT1 PROTEINS;

EID: 84883222978     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2286-2     Document Type: Article

References (33)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57: 43-66.
2. Hezel AF, Zhu AX. Systemic therapy for biliary tract cancers. Oncologist. 2008;13: 415-23.
3. Valle J, Wasan H, Palmer DH, Cunningham D, Anthoney A, Bridgewater J; ABC-02 Trial Investigators. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362: 1273-81.
4. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392: 245-52.
5. Nagayama H, Sato K, Morishita M, Uchimaru K, Oyaizu N, Inazawa T, Yamasaki T, Enomoto M, Nakaoka T, Nakamura T, Maekawa T, Yamamoto A, Shimada S, Saida T, Kawakami Y, Asano S, Tani K, Takahashi TA, Yamashita N. Results of a phase I clinical study using autologous tumour lysate-pulsed monocyte-derived mature dendritic cell vaccinations for stage IV malignant melanoma patients combined with low dose interleukin-2. Melanoma Res. 2003;13: 521-30.
6. Kimura Y, Tsukada J, Tomoda T, Takahashi H, Imai K, Shimamura K, Sunamura M, Yonemitsu Y, Shimodaira S, Koido S, Homma S, Okamoto M. Clinical and immunologic evaluation of dendritic cell-based immunotherapy in combination with gemcitabine and/or S-1 in patients with advanced pancreatic carcinoma. Pancreas. 2012;41: 195-205.
7. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF, Redfern CH, Ferrari AC, Dreicer R, Sims RB, Xu Y, Frohlich MW, Schellhammer PF; IMPACT Study Investigators. Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer. N Engl J Med. 2010;363: 411-22.
8. Kuwabara K, Nishishita T, Morishita M, Oyaizu N, Yamashita S, Yamashita N, et al. Results of a phase I clinical study using dendritic cell vaccinations for thyroid cancer. Thyroid. 2007;17: 53-8.
9. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, Mellman I, Prindiville SA, Viner JL, Weiner LM, Matrisian LM. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res. 2009;15: 5323-37.
10. Nakatsuka S, Oji Y, Horiuchi T, Kanda T, Kitagawa M, Takeuchi T, Kawano K, Kuwae Y, Yamauchi A, Okumura M, Kitamura Y, Oka Y, Kawase I, Sugiyama H, Aozasa K. Immunohistochemical detection of WT1 protein in a variety of cancer cells. Mod Pathol. 2006;19: 804-14.
11. Ghosh M, Kamma H, Kawamoto T, Koike N, Miwa M, Kapoor VK, Krishnani N, Agrawal S, Ohkohchi N, Todoroki T. MUC 1 core protein as a marker of gallbladder malignancy. Eur J Surg Oncol. 2005;31: 891-6.
12. Park SY, Roh SJ, Kim YN, Kim SZ, Park HS, Jang KY, Chung MJ, Kang MJ, Lee DG, Moon WS. Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep. 2009;22: 649-57.
13. Lau SK, Weiss LM, Chu PG. Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study. Am J Clin Pathol. 2004; 122: 61-9.
14. Fan XN, Karsten U, Goletz S, Cao Y. Reactivity of a humanized antibody (hPankoMab) towards a tumor-related MUC1 epitope (TA-MUC1) with various human carcinomas. Pathol Res Pract. 2010;206: 585-9.
15. Matsumura N, Yamamoto M, Aruga A, Takasaki K, Nakano M. Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer. 2002;94: 1770-6.
16. Onodera T, Goseki N, Nosaki G. Prognostic nutritional index in gastro-intestinal surgery of malnourished cancer patients. Nihon Geka Gakkai Zasshi. 1984;85: 1001-5.
17. Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2011;2: 95-101.
18. Okusaka T, Ishii H, Funakoshi A, Yamao K, Ohkawa S, Saito S, Saito H, Tsuyuguchi T. Phase II study of single-agent gemcitabine in patients with advanced biliary tract cancer. Cancer Chemother Pharmacol. 2006;57: 647-53.
19. Lepisto AJ, Moser AJ, Zeh H, Lee K, Bartlett D, McKolanis JR, Geller BA, Schmotzer A, Potter DP, Whiteside T, Finn OJ, Ramanathan RK. A phase I/II study of a MUC1 peptide pulsed autologous dendritic cell vaccine as adjuvant therapy in patients with resected pancreatic and biliary tumors. Cancer Ther. 2008;6: 955-64.
20. Shimizu K, Kotera Y, Aruga A, Takeshita N, Takasaki K, Yamamoto M. Clinical utilization of postoperative dendritic cell vaccine plus activated T-cell transfer in patients with intrahepatic cholangiocarcinoma. J Hepatobiliary Pancreat Sci. 2012;19: 171-8.
21. Berger TG, Schultz ES. Dendritic cell-based immunotherapy. Curr Top Microbiol Immunol. 2003;276: 163-97.
22. Ridgway D. The first 1000 dendritic cell vaccinees. Cancer Invest. 2003;21: 873-86.
23. Hoos A, Eggermont AMM, Janetzki A, Hodi FS, Ibrahim R, Anderson A, Humphrey R, Blumenstein B, Old L, Wolchok J. Improved Endpoints for Cancer Immunotherapy Trials. J Natl Cancer Inst. 2010;102: 1388-97.
24. Hodi FS, Butler M, Oble DA, Seiden MV, Haluska FG, Kruse A, Macrae S, Nelson M, Canning C, Lowy I, Korman A, Lautz D, Russell S, Jaklitsch MT, Ramaiya N, Chen TC, Neuberg D, Allison JP, Mihm MC, Dranoff G. Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients. Proc Natl Acad Sci U S A. 2008;105: 3005-10.
25. Heys SD, Walker LG, Deehan DJ, Eremin OE. Serum albumin: a prognostic indicator in patients with colorectal cancer. J R Coll Surg Edinb. 1998;43: 163-8.
26. Shim HJ, Yun JY, Hwang JE, Bae WK, Cho SH, Chung IJ. Prognostic factor analysis of third-line chemotherapy in patients with advanced gastric cancer. Gastric Cancer. 2011;14: 249-56.
27. Ramacciato G, Corigliano N, Mercantini P, Di Benedetto F, Masetti M, Ercolani G, Lauro A, De Ruvo N, Pinna AD. Prognostic factors after surgical resection for hilar cholangiocarcinoma. Ann Chir. 2006;131: 379-85.
28. Medina-Franco H, Ramos-Gallardo G, Orozco-Zepeda H, Mercado-Díaz MA. Prognostic factor in gallbladder cancer. Rev Invest Clin. 2005;57: 662-5.
29. Fukushima K, Ueno Y, Kawagishi N, Kondo Y, Inoue J, Kakazu E, Ninomiya M, Wakui Y, Saito N, Satomi S, Shimosegawa T. The nutritional index 'COUNT' is useful for predicting long-term prognosis of patients with end-stage liver disease. Tohoku J Exp Med. 2011;224: 215-9.
30. Okada I, Shirahata A, Soda H, Saitou M, Kigawa G, Nemoto H, Sanada Y, Hibi K. Significance of Onodera's prognostic nutritional index for treating unresectable or recurrent colorectal cancer with chemotherapy. Gan To Kagaku Ryoho. 2012;39: 231-5.
31. Kang Sh, Cho KH, Park JW, Yoon KW, Do JY. Onodera's Prognostic Nutritional Index as a Risk Factor for Mortality in Peritoneal Dialysis Patients. J Korean Med Sci. 2012;27: 1354-8.
32. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003;89: 1028-30.
33. Luo Y, Dorf ME. Delayed-type hypersensitivity. Curr Protoc Immunol. 2001; Chapter 4: Unit 4. 5. pp1-5.